LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aandelen Lijst・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Gesloten

28.52 -2.73

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

27.99

Max

29.89

Belangrijke statistieken
By Trading Economics
Inkomsten	43M 13M
Verkoop	29M 107M
EPS	0.25
Winstmarge	12.139
Werknemers	524
EBITDA	16M 8.2M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+121.46% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	17M 1.5B
Vorige openingsprijs	31.25
Vorige sluitingsprijs	28.52

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mei 2026, 21:33 UTC

Winsten

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mei 2026, 21:00 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mei 2026, 20:18 UTC

Winsten

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mei 2026, 23:49 UTC

Marktinformatie

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mei 2026, 23:39 UTC

Marktinformatie

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Global Equities Roundup: Market Talk

27 mei 2026, 23:08 UTC

Marktinformatie

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mei 2026, 22:21 UTC

Marktinformatie

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mei 2026, 21:29 UTC

Populaire aandelen

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mei 2026, 21:08 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mei 2026, 21:02 UTC

Winsten

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mei 2026, 20:59 UTC

Acquisities, Fusies, Overnames

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mei 2026, 20:55 UTC

Winsten

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

27 mei 2026, 20:48 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mei 2026, 20:45 UTC

Winsten

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mei 2026, 20:34 UTC

Acquisities, Fusies, Overnames

Webster Financial Stockholders Approve Sale to Banco Santander

27 mei 2026, 20:32 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mei 2026, 20:30 UTC

Winsten

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mei 2026, 20:30 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mei 2026, 20:22 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:16 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mei 2026, 20:13 UTC

Winsten

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

121.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 65.13 USD 121.46%

Hoogste 100 USD

Laagste 33 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Immunocore Holdings PLC ADR - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.